Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.


Park W., O'Connor C., Chou J., Hilmi M., Tarcan Z., Schwartz C., ...Daha Fazla

Research square, 2025 (Hakemli Dergi) identifier